Agency Information Collection Activities: Submission for OMB Review; Comment Request, 64242-64243 [2022-23054]
Download as PDF
<![CDATA[
64242
Federal Register / Vol. 87, No. 204 / Monday, October 24, 2022 / Notices
lotter on DSK11XQN23PROD with NOTICES1
Contact Person: Megan Lynne Goodall,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 594–8334, megan.goodall@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Drug Discovery and Development.
Date: November 21–22, 2022.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sergei Ruvinov, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4158,
MSC 7806, Bethesda, MD 20892, 301–435–
1180, ruvinser@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Biology of the Eye.
Date: November 21, 2022.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jimok Kim, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6107 Rockledge Drive,
Bethesda, MD 20892, (301) 402–8559,
jimok.kim@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cell Biology, Biochemistry, and
Aging.
Date: November 21, 2022.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kevin Czaplinski, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6901 Rockledge Drive,
Bethesda, MD 20892, (301) 480–9139,
czaplinskik2@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 19, 2022.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–23066 Filed 10–21–22; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:07 Oct 21, 2022
Jkt 259001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Early
Detection Research Network: Clinical
Validation Centers (U01) and Biomarker
Characterization Centers (U2C).
Date: November 16, 2022.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W260, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Robert F. Gahl, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9606 Medical
Center Drive, Room 7W260, Rockville,
Maryland 20850, 240–276–7869, robert.gahl@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; A data
resource for blood and marrow transplants
and adoptive cellular therapy research.
Date: November 17, 2022.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W602, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Delia Tang, M.D.,
Scientific Review Officer, Resources Training
and Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W602,
Rockville, Maryland 20850, 240–276–6456,
tangd@mail.nih.gov.
Name of Committee: National Cancer
Institute Initial Review Group; Cancer
Centers Study Section (A).
Date: December 1–2, 2022.
Time: 10:30 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
7W530, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Shamala K. Srinivas,
Ph.D., Associate Director, Office of Referral,
Review, and Program Coordination, Division
of Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W530, Rockville, Maryland 20850,
240–276–6442, ss537t@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: October 19, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–23068 Filed 10–21–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
Office of Management and Budget
(OMB) review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
documents, email or call the SAMHSA
Reports Clearance Officer at
carlos.graham@samhsa.hhs.gov or (240)
276–0361.
Proposed Project: Program Evaluation
for Prevention Contract (PEPC)—
Strategic Prevention Framework for
Prescription Drugs (SPF-Rx) Evaluation
(OMB No. 0930–0377)—Revision
The Substance Abuse and Mental
Health Services Administration’s
(SAMHSA) Center for Behavioral Health
Statistics and Quality (CBHSQ) aims to
complete a cross-site evaluation of
SAMHSA’s Strategic Prevention
Framework for Prescription Drugs (SPFRx). SPF-Rx is designed to address
nonmedical use of prescription drugs as
well as opioid overdoses by raising
awareness about the dangers of sharing
medications and by working with
pharmaceutical and medical
communities on the risks of
overprescribing. The SPF-Rx program
aims to promote collaboration between
E:\FR\FM\24OCN1.SGM
24OCN1
64243
Federal Register / Vol. 87, No. 204 / Monday, October 24, 2022 / Notices
states/tribes and pharmaceutical and
medical communities to understand the
risks of overprescribing to youth ages
12–17 and adults 18 years of age and
older. The program also aims to enhance
capacity for, and access to, Prescription
Drug Monitoring Program (PDMP) data
for prevention purposes. This request
for data collection includes a revision
from previously approved OMB
instruments.
The SPF-Rx program’s indicators of
success are reductions in opioid
overdoses, reductions in prescription
drug misuse, and improved use of
PDMP data. Data collected through the
tools described in this statement will be
used for the national cross-site
evaluation of SAMHSA’s SPF-Rx
program. This package covers continued
data collection through 2025. The
Program Evaluation for Prevention
Control (PEPC) team will systematically
collect and maintain an Annual
Reporting Tool (ART) and Grantee and
Community Level Outcomes data
modules submitted by SPF-Rx grantees
through the online Data Management
System (DMS).
SAMHSA is requesting approval for
data collection for the SPF-Rx cross-site
evaluation with the following
instruments:
• Annual Reporting Tool (ART)—The
ART is a survey instrument collected
yearly to monitor state, tribal entity, and
community-level performance, and to
evaluate the effectiveness of the SPF-Rx
program. This tool is completed by
grantees and subrecipient community
project directors and provides process
data related to funding use and
effectiveness, organizational capacity,
collaboration with community partners,
data infrastructure, planned
intervention targets, intervention
implementation, evaluation, contextual
factors, training and technical assistance
(T/TA) needs, and sustainability.
• Grantee-and Community-Level
Outcomes Modules—These modules
collect data on key SPF-Rx program
outcomes, including opioid prescribing
patterns and provider use of PDMP.
Grantees will provide outcomes data at
the grantee level for their state, tribal
area, or jurisdiction, as well as at the
community level for each of their
subrecipient communities.
• Grantee-Level Interview—This
qualitative interview will be
administered at the end of the
evaluation to obtain information from
the grantee project directors on their
programs, staffing, populations of focus,
infrastructure, capacity, lessons learned,
and collaboration.
ANNUALIZED DATA COLLECTION BURDEN BY YEAR
Responses
per
respondent
Number of
respondents
Instrument
Annual Reporting Tool .........................................................
a 110
Total number
of responses
Hours per
response
Total burden
hours
Grantee-Level PDMP Outcomes Module ............................
Community-Level PDMP Outcomes Module .......................
Grantee-Level Interview .......................................................
b 21
b 21
1
1
1
5.2
1
FY2023 .........................................................................
131
........................
283
........................
724.5
Annual Reporting Tool .........................................................
a 110
110
21
21
110
N/A
4
3
2.5
1.25
1.5
440
63
52.5
137.5
N/A
b 21
b 21
110
21
21
110
21
4
3
2.5
1.25
1.5
440
63
52.5
137.5
31.5
Grantee-Level PDMP Outcomes Module ............................
Community-Level PDMP Outcomes Module .......................
Grantee-Level Interview .......................................................
b 21
b0
1
1
1
5.2
N/A
FY2024 .........................................................................
131
........................
283
........................
693
Annual Reporting Tool .........................................................
a 110
110
21
21
110
21
4
3
2.5
1.25
1.5
440
63
52.5
137.5
31.5
283
........................
724.5
b 21
b 21
Grantee-Level PDMP Outcomes Module ............................
Community-Level PDMP Outcomes Module .......................
Grantee-Level Interview .......................................................
b 21
b 21
1
1
1
5.2
1
FY2025 .........................................................................
131
........................
b 21
b 21
a Community
lotter on DSK11XQN23PROD with NOTICES1
subrecipient respondent.
b Grantee respondent.
Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
Carlos Graham,
Reports Clearance Officer.
[FR Doc. 2022–23054 Filed 10–21–22; 8:45 am]
BILLING CODE 4162–20–P
VerDate Sep<11>2014
17:07 Oct 21, 2022
Jkt 259001
DEPARTMENT OF HOMELAND
SECURITY
Transportation Security Administration
[Docket No. TSA–2018–0001]
Surface Transportation Security
Advisory Committee (STSAC) Meeting
Transportation Security
Administration, DHS.
ACTION: Committee management; Notice
of Federal Advisory Committee public
meeting.
AGENCY:
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
The Transportation Security
Administration (TSA) will hold a
meeting of the Surface Transportation
Security Advisory Committee (STSAC)
on November 17, 2022. Members of the
STSAC will meet in person at the TSA
Headquarters. A link to virtually
participate in the meeting will be
available to members of the public as
discussed below under SUPPLEMENTARY
INFORMATION/Public Participation. An
agenda for the meeting can also be
found under SUPPLEMENTARY
INFORMATION.
SUMMARY:
E:\FR\FM\24OCN1.SGM
24OCN1
]]>Agencies
[Federal Register Volume 87, Number 204 (Monday, October 24, 2022)]
[Notices]
[Pages 64242-64243]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-23054]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and Mental Health Services
Administration (SAMHSA) will publish a summary of information
collection requests under Office of Management and Budget (OMB) review,
in compliance with the Paperwork Reduction Act (44 U.S.C. chapter 35).
To request a copy of these documents, email or call the SAMHSA Reports
Clearance Officer at [email protected] or (240) 276-0361.
Proposed Project: Program Evaluation for Prevention Contract (PEPC)--
Strategic Prevention Framework for Prescription Drugs (SPF-Rx)
Evaluation (OMB No. 0930-0377)--Revision
The Substance Abuse and Mental Health Services Administration's
(SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ)
aims to complete a cross-site evaluation of SAMHSA's Strategic
Prevention Framework for Prescription Drugs (SPF-Rx). SPF-Rx is
designed to address nonmedical use of prescription drugs as well as
opioid overdoses by raising awareness about the dangers of sharing
medications and by working with pharmaceutical and medical communities
on the risks of overprescribing. The SPF-Rx program aims to promote
collaboration between
[[Page 64243]]
states/tribes and pharmaceutical and medical communities to understand
the risks of overprescribing to youth ages 12-17 and adults 18 years of
age and older. The program also aims to enhance capacity for, and
access to, Prescription Drug Monitoring Program (PDMP) data for
prevention purposes. This request for data collection includes a
revision from previously approved OMB instruments.
The SPF-Rx program's indicators of success are reductions in opioid
overdoses, reductions in prescription drug misuse, and improved use of
PDMP data. Data collected through the tools described in this statement
will be used for the national cross-site evaluation of SAMHSA's SPF-Rx
program. This package covers continued data collection through 2025.
The Program Evaluation for Prevention Control (PEPC) team will
systematically collect and maintain an Annual Reporting Tool (ART) and
Grantee and Community Level Outcomes data modules submitted by SPF-Rx
grantees through the online Data Management System (DMS).
SAMHSA is requesting approval for data collection for the SPF-Rx
cross-site evaluation with the following instruments:
Annual Reporting Tool (ART)--The ART is a survey
instrument collected yearly to monitor state, tribal entity, and
community-level performance, and to evaluate the effectiveness of the
SPF-Rx program. This tool is completed by grantees and subrecipient
community project directors and provides process data related to
funding use and effectiveness, organizational capacity, collaboration
with community partners, data infrastructure, planned intervention
targets, intervention implementation, evaluation, contextual factors,
training and technical assistance (T/TA) needs, and sustainability.
Grantee-and Community-Level Outcomes Modules--These
modules collect data on key SPF-Rx program outcomes, including opioid
prescribing patterns and provider use of PDMP. Grantees will provide
outcomes data at the grantee level for their state, tribal area, or
jurisdiction, as well as at the community level for each of their
subrecipient communities.
Grantee-Level Interview--This qualitative interview will
be administered at the end of the evaluation to obtain information from
the grantee project directors on their programs, staffing, populations
of focus, infrastructure, capacity, lessons learned, and collaboration.
Annualized Data Collection Burden by Year
----------------------------------------------------------------------------------------------------------------
Number of Responses per Total number Hours per Total burden
Instrument respondents respondent of responses response hours
----------------------------------------------------------------------------------------------------------------
Annual Reporting Tool........... \a\ 110 1 110 4 440
\b\ 21 1 21 3 63
Grantee-Level PDMP Outcomes \b\ 21 1 21 2.5 52.5
Module.........................
Community-Level PDMP Outcomes \b\ 21 5.2 110 1.25 137.5
Module.........................
Grantee-Level Interview......... \b\ 21 1 21 1.5 31.5
-------------------------------------------------------------------------------
FY2023...................... 131 .............. 283 .............. 724.5
----------------------------------------------------------------------------------------------------------------
Annual Reporting Tool........... \a\ 110 1 110 4 440
\b\ 21 1 21 3 63
Grantee-Level PDMP Outcomes \b\ 21 1 21 2.5 52.5
Module.........................
Community-Level PDMP Outcomes \b\ 21 5.2 110 1.25 137.5
Module.........................
Grantee-Level Interview......... \b\ 0 N/A N/A 1.5 N/A
-------------------------------------------------------------------------------
FY2024...................... 131 .............. 283 .............. 693
----------------------------------------------------------------------------------------------------------------
Annual Reporting Tool........... \a\ 110 1 110 4 440
\b\ 21 1 21 3 63
Grantee-Level PDMP Outcomes \b\ 21 1 21 2.5 52.5
Module.........................
Community-Level PDMP Outcomes \b\ 21 5.2 110 1.25 137.5
Module.........................
Grantee-Level Interview......... \b\ 21 1 21 1.5 31.5
-------------------------------------------------------------------------------
FY2025...................... 131 .............. 283 .............. 724.5
----------------------------------------------------------------------------------------------------------------
\a\ Community subrecipient respondent.
\b\ Grantee respondent.
Written comments and recommendations for the proposed information
collection should be sent within 30 days of publication of this notice
to www.reginfo.gov/public/do/PRAMain. Find this particular information
collection by selecting ``Currently under 30-day Review--Open for
Public Comments'' or by using the search function.
Carlos Graham,
Reports Clearance Officer.
[FR Doc. 2022-23054 Filed 10-21-22; 8:45 am]
BILLING CODE 4162-20-P
